Oncology is the branch of medicine that deals with the study, diagnosis and treatment of cancer and focuses on the management of cancer from diagnosis through to palliative care.
Cancer is a group of cells (usually derived from a single cell) that has lost its normal control mechanisms. Cancerous cells can develop from any tissue within any organ and can spread throughout the body (metastasise). Cancerous tissue can be divided into those of the blood and blood-forming tissue, and solid tumours, carcinomas or sarcomas, or described as breast cancer including metastatic breast cancer, HER2+, triple negative, gynaecological cancers such as ovarian and cervical, and genitourinary cancer such as prostate cancer.
Featured Learning Zones
Optimising anti-TNF treatment using biosimilars
Biosimilars are uniquely placed to change clinical practice in the fields of gastroenterology, rheumatology, and dermatology. The adoption of biosimilars can improve patient access to the most appropriate treatment, at the optimum time, to ensure the best possible long-term disease outcomes.
Related news and insights
Results from the ongoing phase II DESTINYLung01 trial showed Daiichi Sankyo Company, Limited and AstraZeneca’s Enhertu (fam-trastuzumab deruxtecan-nxki) achieved a clinically meaningful tumor response in patients with HER2 mutant unresectable and/or metastatic non-squamous non-small cell lung cancer (NSCLC) whose disease had progressed following one or more systemic therapies.
VBL Therapeutics announced the presentation of the positive outcome of pre-planned interim analysis results from the OVAL Phase III pivotal clinical trial of VB III in platinum-resistant ovarian cancer at the American Society of Clinical Oncology (ASCO) 2020 virtual annual meeting.
Pfizer reports that following a preplanned efficacy and futility analysis, the independent Data Monitoring Committee (DMC) of the collaborative Phase III early breast cancer PALbociclib CoLlaborative Adjuvant Study (PALLAS) determined that the trial of Ibrance (palbociclib) plus standard adjuvant endocrine therapy is unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival (iDFS).
The pathogenesis of cancer?associated disseminated intravascular coagulation (DIC) is complex and multifactorial. It could present as a spectrum ranging from clinically asymptomatic, but with laboratory markers of coagulation activation...